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ABSTRACT
Proteasome inhibitors have distinct properties and the biochemical consequences 
of suppressing ubiquitin E1 enzymes and the proteasome differ. We compared the 
effects of the proteasome inhibitors bortezomib, ixazomib and carfilzomib and the 
ubiquitin E1 enzyme inhibitor MLN7243/TAK-243 on cell viability and cell death in 
normal keratinocytes and cutaneous squamous cell carcinoma (cSCC) cell lines. The 
effects of both a pulse of treatment and more extended incubation were investigated. 
This is relevant to directly-delivered therapy (topical treatment/intratumoral 
injection) where the time of exposure can be controlled and a short exposure may 
better reflect systemically-delivered inhibitor pharmacokinetics. These agents can 
selectively kill cSCC cells but there are variations in the pattern of cSCC cell line 
sensitivity/resistance. Variations in the responses to proteasome inhibitors are 
associated with differences in the specificity of the inhibitors for the three proteolytic 
activities of the proteasome. There is greater selectivity for killing cSCC cells 
compared to normal keratinocytes with a pulse of proteasome inhibitor treatment than 
with a more extended exposure. We provide evidence that c-MYC-dependent NOXA 
upregulation confers susceptibility to a short incubation with proteasome inhibitors 
by priming cSCC cells for rapid BAK-dependent death. We observed that bortezomib-
resistant cSCC cells can be sensitive to MLN7243-induced death. Low expression of 
the ubiquitin E1 UBA1/UBE1 participates in conferring susceptibility to MLN7243 
by increasing sensitivity to MLN7243-mediated attenuation of ubiquitination. This 
study supports further investigation of the potential of proteasome and ubiquitin 
E1 inhibition for cSCC therapy. Direct delivery of inhibitors could facilitate adequate 
exposure of skin cancers.
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INTRODUCTION
Cutaneous squamous cell carcinoma (cSCC) 
causes significant mortality and morbidity in the general 
population [1]. In addition, cSCC has a huge impact on 
patients with the chronic skin blistering disease recessive 
dystrophic epidermolysis bullosa (RDEB) [2]. The 
cumulative risk of death from cSCC in patients with 
severe generalized RDEB is 80% by the age of 55 [3]. 
Immunosuppressed patients are also at high risk of cSCC. 
For example, organ transplant recipients are up to 150-fold 
more likely to develop cSCC than the general population 
and these tumours tend to be more aggressive [4]. cSCC 
is responsible for 25% of deaths due to skin cancer in the 
United Kingdom and in some regions of the United States 
it is responsible for more deaths than melanoma [1]. Most 
cSCCs can be successfully treated by surgery. However, 
there is a need for improved therapy for the minority of 
cSCCs that are responsible for this substantial health 
burden [5].
Ubiquitination regulates protein stability, activity, 
association and localization [6, 7]. This is important in 
many fundamental processes and pathways of relevance 
to tumorigenesis and cancer therapy. Ubiquitination 
of target proteins involves three classes of enzymes. 
Ubiquitin is loaded onto ubiquitin conjugating enzymes 
(E2s) by ubiquitin activating enzymes (E1s). Ubiquitin 
ligases (E3s) facilitate transfer of ubiquitin from E2s 
to substrates [8, 9]. There are two ubiquitin E1s in the 
human genome: UBA1/UBE1 and UBA6 [10-12]. These 
E1s pass ubiquitin onto overlapping but distinct groups of 
E2s [11, 13]. UBA1 is thought to be involved in ubiquitin 
conjugation to the majority of cellular substrates [11]. 
However, UBA6 is required for the ubiquitination of a 
subset of proteins [13]. UBA6 is also the E1 responsible 
for activation of the ubiquitin-like (UBL) protein 
FAT10 [10, 14]. Ubiquitination can target proteins for 
proteasomal degradation. The proteasome is formed from 
two multi-subunit protein complexes: the 20S core and the 
19S regulatory particle. It has three proteolytic activities 
which are conferred by different subunits in its 20S core: 
PSMB6/β1 (caspase-like), PSMB7/β2 (trypsin-like) and 
PSMB5/β5 (chymotrypsin-like). Protein degradation is 
differentially dependent on these proteolytic activities 
[15, 16]. The chymotrypsin-like activity plays a major 
role in protein degradation but the other activities of the 
proteasome make an additional contribution.
The proteasome inhibitor bortezomib has been 
widely used to treat patients with multiple myeloma. Two 
additional proteasome inhibitors: ixazomib and carfilzomib 
have recently been approved for multiple myeloma 
therapy. These agents differ in their affinity for inhibition 
of the individual proteolytic activities of the proteasome 
and/or in their reversibility. The importance of these 
differences in influencing the therapeutic efficacy of these 
inhibitors is not fully understood. At low concentrations all 
of these compounds inhibit the chymotrypsin-like activity 
of the proteasome. Bortezomib and ixazomib inhibit the 
caspase-like activity at moderately high concentrations 
and the trypsin-like activity at high concentrations [17]. 
Moderately high concentrations of carfilzomib inhibit 
both the caspase and trypsin-like activities [18, 19]. In 
cells the half-life for recovery of the chymotrypsin-like 
activity of the proteasome after inhibitor removal is less 
than 4 hours for ixazomib, 15 to 20 hours for bortezomib 
and can be less than 24 hours for carfilzomib [18-21]. 
Following intravenous injection proteasome inhibitors 
reach μM levels in plasma but the concentration declines 
within hours [22-24]. Binding to proteasomes in patient 
tissues could contribute to this reduction in levels [25]. 
There is a secondary slower phase of elimination and low 
plasma concentrations of proteasome inhibitors can be 
maintained for several days. Effective systemic treatment 
is required for distant cSCC metastasis [26]. There are 
ongoing clinical trials in other cancers, including trials 
involving the more recently developed inhibitors, but to 
date the response of solid tumours in general to systemic 
proteasome inhibitor therapy has been poor [23, 27]. This 
may be related to difficulties in achieving a sufficient 
extent or duration of proteasome inhibition in solid 
tumours by systemic delivery [16, 28]. However, there is 
great potential for treating skin cancer including cSCC by 
topical therapy or intratumoral injection. With directly-
delivered therapy the inhibitor dose and the duration of 
inhibitor exposure could be controlled to achieve optimum 
tumour selectivity [28-31]. Patients with inoperable loco-
regional disease would benefit from effective directly-
delivered drug therapy [32-34]. It would also be useful 
in neoadjuvant and adjuvant settings to reduce the 
impact of surgery and to prevent local tumour recurrence 
[32, 35, 36].
An alternative way of targeting the core ubiquitin-
proteasome system is to inhibit the ubiquitin E1 enzymes 
[37]. Blocking ubiquitin conjugation by suppressing 
ubiquitin E1s has the potential to attenuate all cellular 
events that are controlled by ubiquitination not simply 
proteasomal degradation. Substrate ubiquitination can 
however be differentially dependent on the level of E1 
activity [13, 38]. The cellular pathways affected may 
consequently be determined by the extent of E1 inhibition. 
MLN7243/TAK-243 is a recently developed high-affinity 
inhibitor with selectivity for ubiquitin E1s over other UBL 
protein E1s [39-42]. We confirm in this report that it can 
suppress both UBA1 and UBA6. MLN7243 is the first 
ubiquitin E1 inhibitor to enter a clinical trial for cancer 
therapy (NCT02045095). It has been observed that in 
mice systemically treated with MLN7243 plasma levels 
decline rapidly but the inhibitor has a long half-life in 
tumours [39].
The therapeutic potential for cSCC of targeting the 
ubiquitin-proteasome system has not been adequately 
explored. Furthermore, the anti-tumour activity and the 
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degree of tumour selectivity of proteasome and ubiquitin 
E1 inhibition have not been compared for any cancer type. 
It is common in pre-clinical investigations to determine 
the effect of extended exposure to proteasome inhibitors 
on the viability of cultured cells. It is relevant for directly-
delivered therapy to assess the effects of different times of 
tumour treatment. It may also better model systemically-
delivered inhibitor pharmacokinetics to investigate the 
consequences of a shorter pulse of inhibitor treatment 
[21-24, 39]. Multiple pathways have been implicated 
in killing cells in response to continuous proteasome 
inhibitor exposure [43]. Much remains to be learned 
about the dominant mechanisms underlying sensitivity to a 
pulse of proteasome inhibition. In addition, little is known 
regarding the determinants of sensitivity to ubiquitin E1 
suppression. In this study we compared the effects on cell 
viability and cell death of long and short exposure to the 
three clinically approved proteasome inhibitors and the 
ubiquitin E1 inhibitor MLN7243. This was done in normal 
keratinocytes and in cSCC cell lines derived from RDEB, 
immunocompetent and immunosuppressed patients. 
These agents can selectively kill cSCC cells originating 
from primary and metastatic tumours. There is greater 
selectivity for cSCC compared to normal keratinocytes 
with a pulse of proteasome inhibitor exposure than with 
a more extended treatment. There are differences between 
inhibitors in the magnitude of the window of tumour 
selectivity and in the pattern of sensitivity of cSCC cell 
lines. Mechanisms contributing to these differences were 
identified.
Figure 1: cSCC cell lines can be highly sensitive to a pulse of bortezomib. (A-C) Cells were continuously incubated with 
the proteasome inhibitor bortezomib for 72 hours (Continuous) or treated with bortezomib for 8 hours and then maintained in drug-free 
medium for a further 64 hours (Pulse). Cell viability (live cell number) expressed as a percentage of carrier alone and the percentage of 
dead cells were assayed by real-time imaging. Values are the mean -/+ SEM of 3 independent experiments. (A) Normal keratinocytes from 
an RDEB patient (RDEBK) and cSCC cell lines derived from primary tumours from RDEB patients (SCCRDEB 2, 3 and 4) and from an 
RDEB cSCC metastasis (SCCRDEBMet). (B) Normal human keratinocytes (NHK) and cSCC lines derived from paired primary tumours 
and metastases from immunocompetent (SCCIC1 and SCCIC1Met) and transplant patients (SCCT and SCCTMet). (C) Relative EC50 
values (μM) for reducing cell viability (live cell number) and for promoting cell death. There was little cSCC selectivity with continuous 
exposure to bortezomib but the majority of cSCC cell lines were more sensitive to a pulse of bortezomib than normal keratinocytes. (D) 
The three proteolytic activities of the proteasome were assayed 8 hours after the addition of bortezomib. The results were expressed as 
a percentage of the activity with carrier alone. Values are the mean -/+ SEM of 3 independent experiments. The cSCC cells lines most 
sensitive to pulse of bortezomib were killed at bortezomib concentrations that strongly inhibit both the chymotrypsin and caspase-like 
activities of the proteasome.
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RESULTS
Comparison of the anti-cSCC activity of 
proteasome and ubiquitin E1 inhibitors
We investigated whether there were differences 
in responses to the proteasome inhibitors bortezomib, 
ixazomib and carfilzomib and the ubiquitin E1 inhibitor 
MLN7243. The effects of these agents were assessed 
in untransformed normal keratinocytes from an RDEB 
patient (RDEBK), normal human keratinocytes (NHK) 
and eight cSCC-derived cell lines. cSCCs arise from 
the malignant transformation of keratinocytes in the 
epidermis. Keratinocytes constitute over 90% of cells 
within this layer of the skin. It is consequently appropriate 
to include keratinocytes in the study as the cell of 
cSCC origin and a major normal cell type that would 
be exposed to locally-delivered therapy. Measurement 
of the proteolytic activities of the proteasome verified 
target suppression by proteasome inhibitors (Figure 1D 
and 2D and Supplementary Figure 3D). In addition, we 
confirmed that MLN7243 can reduce the cellular level of 
ubiquitin conjugates (Figure 3D). As part of the catalytic 
mechanism E1 and E2 enzymes form reducing agent-
sensitive thioesters with ubiquitin and UBL proteins [41, 
44]. MLN7243 decreased UBA1 and UBA6 thioesters 
and thioesters of the UBA6 specific E2 UBE2Z/USE1 
(Supplementary Figure 1 and Figure 7). This confirms that 
both UBA1 and UBA6 are inhibited by MLN7243.
Clonogenic assays indicated that a 6 to 8-hour 
treatment with the inhibitors was required for efficient 
anti-cSCC activity (Supplementary Figure 2). To compare 
extended and short exposures cells were continuously 
incubated with inhibitors for 72 hours or treated with 
an 8-hour pulse of these agents and then maintained in 
drug-free culture for a further 64 hours. Cell viability (live 
cell number) and cell death were assayed by real-time 
imaging. Cell viability was generally reduced at a lower 
concentration of the agents than required to promote cell 
death (Figure 1 to 3 and Supplementary Figure 3). This 
reflects greater inhibitor sensitivity of proliferation.
With continuous exposure to bortezomib there was 
little selectivity for cSCC compared to untransformed 
keratinocytes (Figure 1). However, the majority of cSCC 
cell lines were more sensitive to a pulse of bortezomib 
than normal keratinocytes. Indeed, a larger window of 
selectivity for killing sensitive cSCC cells was observed 
with a pulse of bortezomib than with exposure to 
carfilzomib or MLN7243 (Figure 1 to 3). The maximum 
difference in EC50 for killing cSCC cells compared to 
NHK was 110, 30 and 7.5-fold for bortezomib, carfilzomib 
and MLN7243 respectively. Furthermore, in half of the 
cSCC cell lines the EC50 for bortezomib-induced cell 
death was at least 30-fold lower than for NHK. However, 
death in SCCRDEBMet and SCCIC1Met cells was 
insensitive to a short bortezomib exposure.
The general pattern of ixazomib susceptibility in 
normal keratinocytes and representative cSCC cell lines 
was similar to that of bortezomib (Supplementary Figure 
3). Under the conditions used the reduction in viability 
and the level of death observed in bortezomib/ixazomib-
sensitive SCCRDEB4 cells with a short exposure to low 
concentrations of ixazomib was less than that with a 
pulse of bortezomib (Supplementary Figure 3 and Figure 
1). This may be related to the faster dissociation rate of 
ixazomib as the specificity of bortezomib and ixazomib 
for the proteolytic activities of the proteasome are very 
similar (Figure 1D and Supplementary Figure 3D) [18-21].
Carfilzomib was more generally selective for killing 
cSCC cells compared to normal keratinocytes than the 
other agents tested (Figure 2). The cSCC selectivity was 
greater with continuous exposure to carfilzomib than 
with continuous exposure to bortezomib. Under these 
conditions the EC50 values for killing cSCC cells were 
3 to 14-fold lower than for NHK with carfilzomib and a 
maximum of 2.5-fold lower with bortezomib (Figure 1 and 
2). RDEB cSCC cell lines were particularly susceptible to 
death induced by continuous treatment with carfilzomib. A 
pulse of carfilzomib exposure resulted in further increases 
in cSCC selectivity and all cSCC cell lines were killed 
at substantially lower concentrations of carfilzomib than 
normal keratinocytes. With a short carfilzomib exposure 
the EC50 values for killing cSCC cells were 4.5 to 30-fold 
lower than for NHK.
The ubiquitin E1 inhibitor MLN7243 selectively 
killed a subset of cSCC lines (Figure 3). SCCT and 
SCCRDEBMet cells were the most susceptible to 
continuous treatment with MLN7243. SCCIC1Met cells 
were also selectively killed by an extended exposure to 
this agent. Death in SCCRDEBMet cells displayed the 
greatest sensitivity to a pulse of MLN7243. There were 
striking differences between responses to this inhibitor 
and bortezomib: MLN7243-sensitive SCCRDEBMet and 
SCCIC1Met cells were the most resistant to bortezomib 
(Figure 1 and 3). Conversely, SCCIC1 cells were 
susceptible to a pulse of bortezomib but were highly 
resistant to ubiquitin E1 inhibition.
These results indicate that a good window of 
selectivity can be achieved with the inhibitors for the 
killing of cSCC cells derived from primary and metastatic 
tumours compared to normal keratinocytes but that there 
are differences in the pattern of inhibitor sensitivity. 
Clonogenic assays confirmed variations in inhibitor 
sensitivity observed in the shorter-term real-time imaging 
assays (Figure 4).
The proteolytic activities of the proteasome 
were assayed at the end of an 8-hour treatment with 
proteasome inhibitors, which corresponds to the length 
of the pulse used for viability/cytotoxicity assays (Figure 
1D and 2D and Supplementary Figure 3D). At low doses 
carfilzomib is more specific for the chymotrypsin-like 
activity than bortezomib and ixazomib which could 
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underlie the greater cSCC selectivity of continuous 
carfilzomib exposure (Figure 1 and 2 and Supplementary 
Figure 3). Bortezomib and ixazomib had similar effects 
on the proteolytic activities of the proteasome (Figure 
1D and Supplementary Figure 3D). Death resulting from 
a pulse of bortezomib or ixazomib exposure in the most 
sensitive cSCC cells occurred at inhibitor concentrations 
that profoundly inhibit both the chymotrypsin and 
caspase-like activities while having a relatively 
modest effect on the trypsin-like activity (Figure 1 and 
Supplementary Figure 3). Killing of normal keratinocytes 
and resistant cSCC cells was linked with further 
inhibition of the trypsin-like activity at high inhibitor 
concentrations. Death in cSCC cells exposed to a pulse 
of carfilzomib was associated with strong inhibition of 
the chymotrypsin-like activity and moderate inhibition 
of both the caspase and trypsin-like activities (Figure 2). 
Carfilzomib-dependent death in normal keratinocytes 
was linked with progressive inhibition of the residual 
activities. A pulse of proteasome inhibitor treatment that 
specifically blocked the chymotrypsin-like activity of the 
proteasome caused little or no death in cSCC cell lines. 
This is consistent with observations in myeloma and 
breast cancer cells [16, 21]. These results indicate that 
the level of cSCC selectivity of a pulse of proteasome 
inhibitor treatment is influenced by the differential 
dependency for survival in sensitive tumour cells and 
normal keratinocytes on the proteolytic activities of the 
proteasome. Differences in the profile of inhibition of the 
proteolytic activities of the proteasome could contribute 
to the observed variations in cSCC susceptibility to 
bortezomib/ixazomib and carfilzomib.
Figure 2: Carfilzomib exhibits more general anti-cSCC selectivity than bortezomib. (A-C) Cells were continuously incubated 
with the proteasome inhibitor carfilzomib or treated with an 8-hour carfilzomib pulse. Cell viability (live cell number), expressed as a 
percentage of carrier alone and the percentage of dead cells were assayed by real-time imaging 72 hours after drug addition. Values are the 
mean -/+ SEM of 3 independent experiments. (A) Normal keratinocytes and cSCC cell lines from RDEB patients. (B) Normal keratinocytes 
and cSCC cell lines from: immunocompetent (SCCIC) and transplant (SCCT) patients. (C) Relative EC50 values (μM) for reducing cell 
viability (live cell number) and for promoting cell death. cSCC cell lines were more sensitive to continuous carfilzomib treatment and a 
pulse of carfilzomib exposure than normal keratinocytes. (D) The proteolytic activities of the proteasome were assayed 8 hours after the 
addition of carfilzomib. The results were expressed as a percentage of the activity with carrier alone. Values are the mean -/+ the range of 
2 independent experiments. Cell death in RDEB cSCC cell lines in response to continuous exposure to carfilzomib occurred at carfilzomib 
concentrations where only the chymotrypsin-like activity was inhibited. Death of cSCC cells induced by a short pulse of carfilzomib was 
associated with robust inhibition of the chymotrypsin-like activity and moderate inhibition of both the caspase and trypsin-like activities.
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c-MYC, NOXA and BAK participate in killing 
cSCC cells in response to a pulse of treatment 
with proteasome inhibitors
We next aimed to identify mechanisms involved in 
determining sensitivity/resistance to a pulse of treatment 
with proteasome inhibitors. Basal levels of bulk high 
molecular weight ubiquitin conjugates were elevated 
in three of the eight cSCC cell lines (Supplementary 
Figure 4A). There was a general increase in cSCC cells 
compared to normal keratinocytes of free monomeric 
ubiquitin, proteasome subunits and Ser51 phosphorylated 
eiF2ɑ (Supplementary Figure 4). Increased P-eiF2ɑ is 
consistent with elevated proteotoxic stress in cSCC cells 
[45]. These changes may reflect a greater demand for 
proteasomal degradation in the tumour cells compared to 
normal keratinocytes which could contribute to the greater 
sensitivity of cSCC cells to proteasome inhibition. However, 
there was no clear association between these alterations and 
the resistance of SCCRDEBMet and SCCIC1Met cells to a 
pulse of bortezomib treatment. Resistance in these cells was 
not due to a failure of bortezomib to inhibit the proteasome 
(Figure 1D). Bortezomib-dependent accumulation of bulk 
high molecular weight ubiquitin conjugates and the return 
to baseline levels of conjugates after inhibitor removal were 
indistinguishable in bortezomib-sensitive and resistant 
cells (Figure 6 and Supplementary Figure 5). Proteasome 
inhibition reduces the level of mono-ubiquitinated histone 
H2A/H2B due to depletion of the pool of free ubiquitin 
[46, 47]. Ubiquitination of these histones is involved in 
regulation of transcription and DNA damage responses 
[48]. The pattern of loss and recovery of histone H2A/H2B 
ubiquitination was also indistinguishable in bortezomib-
resistant and sensitive cells (Figure 6 and Supplementary 
Figure 5). Histone H2A/H2B ubiquitination was recovered 
even with continuous exposure to bortezomib. There 
are compensatory mechanisms which act to restore free 
ubiquitin levels upon proteasome inhibition [49, 50].
Figure 3: Bortezomib-resistant cSCC cells can be sensitive to MLN7243. (A-C) Cells were continuously incubated with the 
ubiquitin E1 inhibitor MLN7243 or treated with an 8-hour MLN7243 pulse. Cell viability (live cell number), expressed as a percentage of 
carrier alone and the percentage of dead cells were assayed by real-time imaging 72 hours after drug addition. Values are the mean -/+ SEM 
of 3 independent experiments. (A) Normal keratinocytes and cSCC cell lines from RDEB patients. (B) Normal keratinocytes and cSCC 
cell lines from: immunocompetent (SCCIC) and transplant (SCCT) patients. (C) Relative EC50 values (μM) for reducing cell viability (live 
cell number) and for promoting cell death. SCCT cells and bortezomib-resistant SCCRDEBMet and SCCIC1Met cells were sensitive to 
death induced by MLN7243. (D) Cells were treated with carrier (-) or 0.1μM MLN7243 (+) for 12 hours and analysed by western blotting. 
Consistent with ubiquitin E1 inhibition MLN7243 reduced high molecular weight ubiquitin conjugates and ubiquitinated histone H2A/H2B 
and increased free ubiquitin.
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To identify mediators of bortezomib sensitivity 
we explored the effect of knockdown of 40 candidate 
regulators on the response to bortezomib (data not 
shown). In bortezomib-sensitive SCCRDEB4 and 
SCCIC1 cells siRNA-mediated depletion of c-MYC and 
the pro-apoptotic proteins NOXA and BAK was found to 
attenuate cell death in response to a pulse of bortezomib 
(Figure 5A). BAK is an apoptosis effector that regulates 
mitochondrial membrane permeability [51]. siRNAs 
targeting other apoptosis effectors BAX and BOK did not 
diminish bortezomib-dependent cell death in SCCRDEB4 
cells (Supplementary Figure 6). A particular dependence 
on BAK is consistent with previous observations in 
mesothelioma [52]. c-MYC and NOXA are both degraded 
by the proteasome [53-55]. NOXA is a transcriptional 
target of c-MYC and NOXA activates BAK by binding to 
the BAK repressor MCL-1 [56, 57]. In SCCRDEB4 and 
SCCIC1 cells a cytotoxic concentration of bortezomib 
increased c-MYC and NOXA protein expression within 8 
hours of drug treatment (Figure 5B). Depletion of c-MYC 
reduced the level of NOXA accumulated by bortezomib 
indicating that c-MYC participates in NOXA upregulation. 
This is consistent with a role of c-MYC/NOXA/BAK 
acting in a common pathway to mediate cell death in 
response to a pulse of bortezomib.
Basal expression of c-MYC and NOXA was 
low in bortezomib-resistant normal keratinocytes and 
SCCIC1Met cells and BAK levels were low in the 
bortezomib-resistant SCCRDEBMet cell line (Figure 
5C). Low expression of one or more of these proteins 
could contribute to resistance to a pulse of bortezomib 
treatment. c-MYC expression was increased in all cSCC 
cell lines with elevated NOXA and knockdown of c-MYC 
reduced basal NOXA expression (Figure 5B and 5C). This 
indicates that c-MYC is required to maintain elevated 
basal levels of NOXA. cSCC cell lines sensitive to a 
Figure 4: Differences in cSCC cell line sensitivity to proteasome and ubiquitin E1 inhibitors are recapitulated in 
clonogenic assays. Cells were treated with inhibitors for 72 or 8 hours, comparable to the previously used extended exposure and pulse 
respectively. Cells were then maintained in drug-free medium to allow colony formation. The pattern of inhibitor sensitivity was similar 
to that observed using shorter-term real-time imaging assays. SCCIC1 cells were relatively sensitive to proteasome inhibitors but resistant 
to the ubiquitin E1 inhibitor MLN7243. SCCRDEB4 cells are highly sensitive to proteasome inhibitors and intermediately sensitive to 
MLN7243. SCCRDEBMet cells were insensitive to an 8-hour treatment with bortezomib or ixazomib but sensitive to an 8-hour exposure 
to carfilzomib. SCCRDEBMet cells were sensitive to 8 and 72 hours treatment with MLN7243.
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Figure 5: c-MYC-mediated NOXA upregulation is required for BAK-dependent cell death in response to a pulse of 
bortezomib. (A) SCCRDEB4 and SCCIC1 cells, in which cell death is sensitive to a pulse of bortezomib, were mock-transfected (-) or 
transfected with a non-targeting siRNA (Control) or siRNAs targeting c-MYC, NOXA and BAK. siRNAs 1 to 3 are complementary to 
different sequences within the indicated target. Cells were exposed to an 8-hour pulse of bortezomib and cell death was assessed 24 hours 
after drug addition by real-time imaging. Values are the mean -/+ SEM of at least 3 independent experiments. Knockdown of c-MYC, 
NOXA, and BAK attenuated cell death in response to a short exposure to bortezomib (* P < 0.05 and *** P < 0.005 compared with control 
siRNA transfected cells). (B) SCCRDEB4 and SCCIC1 cells were mock-transfected (-) or transfected with non-targeting control siRNA or 
siRNAs complementary to c-MYC. Cells were treated with carrier or bortezomib (BZ) and were analysed by western blotting 8 hours after 
drug addition. A cytotoxic concentration of bortezomib (0.1μM) caused c-MYC-dependent accumulation of NOXA. (C) The expression 
of the indicated proteins was analysed by western blotting in the panel of cells used in this study. NHK (1) and (2) are from two different 
donors. Bortezomib-resistant normal keratinocytes and SCCIC1Met cells expressed low levels of c-MYC and NOXA while bortezomib-
resistant SCCRDEBMet cells had low BAK levels.
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pulse of bortezomib died faster than resistant cells when 
exposed to continuous bortezomib treatment (Figure 6A 
and 6B). This was associated with the accumulation of 
NOXA at earlier time points in cells sensitive to a pulse 
of bortezomib (Figure 6B). These results suggest that 
cells can be sensitive to a pulse of bortezomib because 
they die rapidly in response to bortezomib treatment. High 
expression of c-MYC/NOXA may confer sensitivity to a 
short bortezomib exposure by priming cSCC cells for fast 
bortezomib-mediated cell death.
c-MYC/NOXA/BAK also contribute to promoting 
rapid cell death in response to a pulse of carfilzomib 
treatment in bortezomib-sensitive cSCC cells 
(Supplementary Figure 7). In carfilzomib-sensitive 
but bortezomib-resistant SCCRDEBMet cells death 
in response to a pulse of carfilzomib was not affected 
by targeting c-MYC, NOXA or BAK (Supplementary 
Figure 7A). This indicates that short-term treatment 
with carfilzomib can kill these cells through another 
mechanism. The engagement of an alternative mechanism 
of cell death, possibly due to differences in the pattern 
of proteasome inhibition, could account for the 
greater sensitivity of SCCRDEBMet cells to a pulse of 
carfilzomib.
UBA1 protein levels influence sensitivity to 
MLN7243
To identify determinants of sensitivity to MLN7243 
the protein expression of the ubiquitin E1 UBA1 was 
compared in the panel of cells used in this study (Figure 
7A). Two major isoforms of UBA1 are generated from 
a common mRNA as a result of alternative start codon 
usage [58-60]. UBA1A is localised in the nucleus and the 
Figure 6: Early induction of NOXA is associated with rapid cell death in cells sensitive to a pulse of bortezomib. (A) 
NHK, RDEBK and cSCC cell lines were continuously treated with 0.1 μM bortezomib. The number of dead cells was determined at the 
indicated time points by real-time imaging. The results are expressed as a percentage of the maximum number of dead cells for each cell 
type. Values are the mean -/+ SEM of 3 independent experiments. cSCC cell lines sensitive to a pulse of bortezomib die more rapidly 
than bortezomib-resistant: normal keratinocytes, SCCRDEBMet cells and SCCIC1Met cells. (B) cSCC cell lines resistant to a pulse of 
bortezomib (NHK and SCCIC1Met) and lines sensitive to a short treatment with bortezomib (SCCIC1 and SCCRDEB4) were continuously 
incubated with carrier (DMSO) or 0.1 μM bortezomib (BZ) for up to 48 hours. The level of ubiquitin and ubiquitin conjugates and the 
expression of the indicated proteins was analysed by western blotting. Bortezomib caused the accumulation of high molecular weight 
ubiquitin conjugates in all cells irrespective of their bortezomib-susceptibility. NOXA induction and PARP and caspase 3 cleavage occurred 
at earlier time points in bortezomib-sensitive cells confirming more rapid apoptosis induction.
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cytoplasm. UBA1B lacks the 40 N-terminal amino acid 
residues of UBA1A and is predominantly cytoplasmic. 
In cSCC cells there was an inverse association between 
MLN7243 sensitivity and UBA1 expression. UBA1A and 
B expression was low in SCCRDEBMet and SCCT cells 
which were the most MLN7243-sensitive. SCCRDEBMet 
cells had the lowest levels of both UBA1 isoforms and 
death in these cells was the most sensitive to a pulse of 
MLN7243 (Figure 3). Conversely, UBA1A expression 
was high in the SCCIC1 and SCCRDEB3 lines which 
were the most MLN7243-resistant. Knockdown of 
UBA1A and B in these MLN7243-resistant lines 
dramatically increased sensitivity to the effects of the 
E1 inhibitor on cell viability and death (Figure 7B and 
7C). The level of UBA1 expression attained following 
siRNA-mediated knockdown in these resistant lines and 
the resulting susceptibility to MLN7243 were comparable 
to those in MLN7243-sensitive SCCRDEBMet cells 
(Figure 3 and 7B and 7C). Consistent with inhibition of 
ubiquitin E1s, MLN7243 decreased the level of DTT-
sensitive UBA1 species (UBA1-ubiquitin thioesters) 
along with high molecular weight ubiquitin conjugates 
and ubiquitinated histones H2A/H2B while the level of 
free monomeric ubiquitin was increased (Figure 7D). 
These effects occurred at lower MLN7243 concentrations 
in sensitive SCCRDEBMet cells than in resistant 
SCCIC1 cells. UBA1 knockdown in SCCIC1 cells 
reduced the concentration of MLN7243 required to 
attenuate ubiquitination. In all circumstances cell death 
occurred at doses of MLN7243 that diminished ubiquitin 
conjugates. These results indicate that UBA1 levels are 
a major determinant of the sensitivity of cSCC cells to 
MLN7243 due to their influence on the concentration of 
this agent required to inhibit ubiquitination. In contrast, 
UBA6 protein expression was relatively uniform across 
the panel of cells (Supplementary Figure 8A). Knockdown 
of UBA6 in MLN7243-resistant SCCIC1 and SCCRDEB3 
cells did not alter their sensitivity to the E1 inhibitor 
(Supplementary Figure 8B and 8C). This indicates that 
UBA6 protein levels are not a determinant of MLN7243 
sensitivity in these cell lines.
Knockdown of UBA1 did not greatly alter the 
pattern of bulk high molecular weight ubiquitin conjugates 
in cSCC cells, even in the SCCRDEBMet line which 
expresses the lowest endogenous levels of the E1 (Figure 
7 and Supplementary Figure 9). In addition, knockdown of 
UBA6 alone and in combination with UBA1 did not alter 
high molecular weight ubiquitination in SCCRDEBMet 
cells (Supplementary Figure 9B). This suggests that 
ubiquitin E1s are not normally rate-limiting for the 
formation of these ubiquitin conjugates in the cSCC 
cell lines tested and that in these cells E1 activity needs 
to be strongly inhibited in order for ubiquitination to be 
attenuated. Levels of ubiquitinated histone H2A/H2B 
were reduced by knockdown of UBA1 (Figure 7B and 7D 
and Supplementary Figure 9). A decrease in ubiquitinated 
histone H2A/H2B could provide a sensitive readout of 
UBA1 suppression.
DISCUSSION
We compared the effects in normal keratinocytes 
and cSCC cell lines of a long and short treatment with 
proteasome inhibitors and the ubiquitin E1 inhibitor 
MLN7243. We show that a pulse of proteasome inhibitor 
exposure results in greater selectivity for killing cSCC 
cells than a more extended exposure. In sensitive cSCC 
cell lines a pulse of bortezomib treatment gives the highest 
level of selectivity compared to normal keratinocytes but 
some cSCC cell lines are bortezomib-resistant. These 
bortezomib-resistant tumour cells can be sensitive to 
MLN7243. Carfilzomib is more generally cSCC selective 
than bortezomib or MLN7243. We provide evidence 
that c-MYC, NOXA and BAK are determinants of 
susceptibility to a pulse of proteasome inhibition and that 
low UBA1 expression confers susceptibility to MLN7243.
This study indicates that the cSCC selectivity of 
a pulse of proteasome inhibitor exposure is related to a 
differential dependency for survival of sensitive cSCC 
cells and normal keratinocytes on the proteolytic activities 
of the proteasome. For example, killing of the most 
bortezomib-sensitive cSCC cell lines by a short treatment 
with bortezomib occurs at inhibitor concentrations that 
markedly attenuate the chymotrypsin and caspase-like 
activities but only modestly inhibit the trypsin-like activity. 
In normal keratinocytes death is associated with inhibition 
of all three activities at high bortezomib concentrations. 
This suggests that the window of selectivity for cSCC 
cells compared to normal keratinocytes can be determined 
by the specificity of inhibitors for the activities of the 
proteasome. For instance, a small molecule which inhibits 
the chymotrypsin and caspase-like activities without 
substantially inhibiting the trypsin-like activity may show 
even greater selectivity for sensitive cSCC cells than 
bortezomib. These results are consistent with the previous 
finding that inhibition of different individual proteolytic 
activities and combinations of proteolytic activities of 
the proteasome results in distinct degrees of interference 
with protein degradation [15, 16]. The extent to which 
the proteolytic activities are inhibited could consequently 
influence which cellular pathways are affected and the 
strength of their modulation.
We observed that concentrations of bortezomib and 
carfilzomib that kill cSCC cell lines have divergent effects 
on the proteolytic activities of the proteasome. Variations 
in the extent to which cellular pathways are affected due 
to these differences in proteasome inhibition may underlie 
the greater cSCC selectivity of continuous exposure to 
carfilzomib and the ability of a pulse of carfilzomib to kill 
cSCC cells resistant to a short treatment with bortezomib. 
Consistent with this, our study indicates that a pulse of 
carfilzomib can induce cell death by different mechanisms 
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Figure 7: Low UBA1 protein expression is a determinant of sensitivity to MLN7243. (A) The expression of UBA1 in the panel 
of cells used in this study was analysed by western blotting. This was carried out using a primary antibody that detects both major UBA1 
isoforms: UBA1A (upper band) and UBA1B (lower band) and an antibody that is specific for UBA1A. UBA1A and B expression was lowest 
in MLN7243-sensitive SCCRDEBMet and SCCT cells while UBA1A expression was high in MLN7243-resistant SCCRDEB3 and SCCIC1 
cells. (B) MLN7243-resistant SCCIC1 and SCCRDEB3 cells were mock-transfected (-) or transfected with the indicated siRNAs. UBA1 
siRNAs 1 to 4 are complementary to different UBA1 sequences. Ubiquitin E1 expression and the pattern of ubiquitination were analysed 
by western blotting 72 hours after transfection. The UBA1 siRNAs efficiently depleted UBA1 while having no effect on the level of UBA6 
or bulk high molecular weight ubiquitin conjugates. (C) MLN7243-resistant SCCIC1 and SCCRDEB3 cells were transfected with siRNAs 
targeting UBA1. Cell viability (live cell number) expressed as a percentage of carrier alone for each siRNA and cell death were analysed 
by real-time imaging 72 hours after the initiation of continuous incubation with MLN7243. Values are the mean -/+ SEM of 3 experiments. 
Knockdown of UBA1 dramatically increased sensitivity to MLN7243. (D) MLN7243-sensitive SCCRDEBMet cells and MLN7243-resistant 
SCCIC1 cells were transfected with the indicated siRNAs. Samples were analysed by western blotting for UBA1 and ubiquitin 12 hours 
after initiating continuous incubation with MLN7243. More slowly migrating UBA1-ubiquitin thioesters were preserved by running samples 
in the absence of reducing agent (-DTT). MLN7243 decreased UBA1 thioesters. Cells with low UBA1 expression were more sensitive to 
MLN7243-induced decreases in high molecular weight ubiquitin conjugates and ubiquitinated histone H2A/H2B.
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in bortezomib-resistant and bortezomib-sensitive cells. 
Differences in the mechanisms through which distinct 
proteasome inhibitors kill cells have been observed 
previously [61].
c-MYC, NOXA and BAK promote cell death in 
response to an extended exposure to bortezomib in a 
number of cancer types [43, 52, 54, 55, 57, 62, 63]. This 
study confirms that this pathway can play an important role 
in mediating cell death induced by a pulse of bortezomib. 
In addition, we observed that this pathway can also 
participate in killing bortezomib-sensitive cSCC lines by 
a pulse of carfilzomib. c-MYC and NOXA levels are low 
in normal keratinocytes which provides a mechanism for 
tumour selectivity. Furthermore, cSCC cell lines resistant 
to a pulse of bortezomib have low basal levels of c-MYC 
and NOXA or BAK. Low basal expression of these 
proteins is consequently a potential marker for bortezomib 
resistance in cSCCs. In support of this, a decrease in 
c-MYC and NOXA expression is involved in the acquired 
resistance of mesothelioma cells to bortezomib [52]. 
Encouragingly, c-MYC protein expression is upregulated 
in 75 to 85% of cSCCs and BAK protein is expressed in 
95% of cSCCs [64-67]. Our results indicate that cells are 
sensitive to a pulse of bortezomib because they undergo 
more rapid bortezomib-induced death than resistant 
cells. Early c-MYC-dependent accumulation of the BAK 
activator NOXA contributes to promoting quicker cell 
death in bortezomib-sensitive cells. Both c-MYC and 
NOXA are degraded by the proteasome and c-MYC 
promotes NOXA transcription. Upregulation of basal 
NOXA mRNA expression by elevated c-MYC could 
contribute to fast protein accumulation upon inhibition 
of the proteasomal degradation of NOXA. Proteasome 
inhibition also increases c-MYC transcriptional activity 
towards the NOXA gene [52, 57, 68].
The pattern of sensitivity of cSCC cells to ubiquitin 
E1 inhibition is different from proteasome inhibitors. The 
two cSCC cell lines most resistant to a pulse of bortezomib 
are among the most sensitive to MLN7243-induced cell 
death. We observed that low expression of both UBA1A 
and B isoforms is associated with MLN7243 sensitivity 
and high expression of UBA1A with MLN7243 resistance. 
Furthermore, knockdown of UBA1A and B confers 
MLN7243 sensitivity to resistant cSCC cells. MLN7243-
induced cell death is associated with a reduction in the 
level of ubiquitin conjugates. A lower concentration of 
MLN7243 is required to diminish ubiquitination in cSCC 
cells with low UBA1 expression. UBA1 protein levels 
may thus provide a marker for tumour sensitivity to 
MLN7243. It would be of great interest to determine the 
mechanisms responsible for the observed differences in 
UBA1A and B expression. A better understanding of how 
levels of UBA1 isoforms are regulated could lead to the 
development of therapeutic interventions that modulate 
their expression. This may provide a means to enhance 
tumour sensitivity or increase the resistance of normal 
cells to MLN7243. UBA1 and UBA6 are both inhibited 
by MLN7243. While our study supports a pre-eminent 
role of UBA1 in determining the sensitivity of cSCC 
cells to MLN7243 under some circumstances suppression 
of UBA6 could contribute to the anti-tumour activity of 
this inhibitor. UBA6 can play a non-redundant role in 
maintaining cell viability [10, 69].
A high degree of E1 suppression is required to 
reduce bulk high molecular weight ubiquitin conjugates 
in the cSCC cell lines examined. This indicates that 
the ubiquitin E1s are not normally rate-limiting for 
these ubiquitination events. This is consistent with 
previous studies [38]. UBA1 is a highly active enzyme 
and it is able to charge excess amounts of E2s with 
ubiquitin [70]. There are examples of cancer-derived 
cells, including acute and chronic myeloid leukaemia 
cell lines where UBA1 is closer to rate-limiting for 
ubiquitination [37]. These cancers may be highly 
sensitive to MLN7243.
This study indicates that there is therapeutic 
potential for proteasome and UBA1 inhibition for cSCC. 
Future work could initially be aimed at developing direct 
delivery of inhibitors to tumours. This would overcome 
limitations of systemic delivery and allow optimal 
exposure of cSCCs. Effective directly-delivered therapy 
would be of benefit to cSCC patients and it would inform 
systemic therapy for treating cSCC and other solid 
tumours.
MATERIALS AND METHODS
Cell culture
Normal keratinocytes (NHK and RDEBK) and 
cSCC cell lines were isolated and maintained as described 
[71, 72]. Cells were routinely grown at 37oC and 5% 
CO2 in a humidified atmosphere in keratinocyte medium 
containing 10% serum and growth factors [72]. Normal 
keratinocytes were grown in the presence of a mitotically 
inactivated 3T3 fibroblast feeder layer. RDEBK were 
expanded using the ROCK inhibitor Y-27632 (1254: 
Tocris Bioscience, Bristol, UK) which was removed 48 
hours prior to the initiation of experiments [73]. cSCC 
cell lines were cultured in the absences of feeder cells. 
SCCRDEBMet (SCCRDEB70) and RDEBK cells were 
a gift from Dr Andrew P. South (Thomas Jefferson 
University). The tissue from which these cells were 
derived was provided by Jemima E. Mellerio (King’s 
College London) and Julio C. Salas-Alanís (DEBRA 
Mexico). SCCT (MET1) and SCCTMet (MET4) cell lines 
were described previously [74]. SCCIC1/SCCIC1Met 
and SCCT/SCCTMet cell lines are derived from paired 
primary tumours and their metastases. For experiments, 
cells were plated in the absence of feeders in keratinocyte 
medium containing 10% serum and growth factors with 
no added EGF.
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Inhibitor treatment
Inhibitors were dissolved in DMSO (20 to 50 mM 
stocks). Unless otherwise indicated cells were treated with 
inhibitors 16 to 24 hours after plating. Compounds used 
in this study were: bortezomib (B-1408: LC Laboratories 
Woburn, MA, USA), carfilzomib (S2853: Selleckchem, 
Houston, TX, USA), ixazomib (S2180: Selleckchem) and 
MLN7243 (CT-M7243: Chemietek, Indianapolis, IN, USA).
siRNA transfection
Dharmacon ON-TARGETplus modified siRNAs 
(Thermo Fisher Scientific, Waltham, MA, USA) were 
used in this work and are listed in Supplementary Figure 
10. Reverse transfection with synthetic siRNA duplexes 
(10 nM) was carried out using Invitrogen Lipofectamine 
RNAiMAX transfection reagent (13778150: Thermo 
Fisher Scientific) according to the manufacturer’s 
instructions. Inhibitors were added 48 hours after 
transfection to ensure target knockdown before initiating 
drug treatment.
Cell viability assays
Cells were seeded into 96 well plates and live cell 
number and cell death were analysed according to the 
manufacturers’ instructions with an IncuCyte ZOOM real-
time imager (Essen BioScience Ltd, Welwyn Garden City, 
UK) using the CellTox Green Cytotoxicity Assay (G8731: 
Promega, Southampton, UK). Relative EC50 values were 
determined using GraphPad Prism (GraphPad Software 
Inc, La Jolla, CA, USA). For clonogenic assays cells were 
seeded into six well plates. Inhibitors were added for the 
indicated times and then cells were maintained in drug-
free medium for up to 2 weeks to allow colony formation. 
Colonies were fixed in 10% methanol, 10% acetic acid 
and stained with crystal violet.
Statistical analysis
The statistical significance of differences between 
two groups (control and targeting siRNA) was determined 
using a one tailed T-test.
Proteasome activity measurements
The three proteolytic activities of the proteasome 
were measured in parallel in cells seeded in 96 well plates 
using the Cell-Based Proteasome-Glo Assay (G1180: 
Promega). Medium from wells containing no cells was 
used as a blank.
Western blotting
The primary antibodies used are listed in 
Supplementary Figure 10. Cell extracts were prepared by 
direct lysis into SDS electrophoresis sample buffer: 100 
mM Tris pH 6.8, 4% SDS, 20% glycerol, 20 mM EDTA, 
0.014% bromophenol blue. Western blotting was carried 
out as described previously [75]. Membranes probed for 
ubiquitin were boiled for 30 minutes in de-ionized water 
prior to blocking to increase epitope exposure.
Abbreviations
Bortezomib (BZ), cutaneous squamous cell 
carcinoma (cSCC), mono-ubiquitinated histone H2A/
H2B (uH2A/B), normal human keratinocytes (NHK), 
recessive dystrophic epidermolysis bullosa (RDEB), 
recessive dystrophic epidermolysis bullosa keratinocytes 
(RDEBK), squamous cell carcinoma immunocompetent 
(SCCIC), squamous cell carcinoma recessive dystrophic 
epidermolysis bullosa (SCCRDEB), squamous cell 
carcinoma transplant (SCCT) and ubiquitin-like (UBL).
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